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Abstract Restriction factors comprise an important layer
of host defense to fight against viral infection. Some
restriction factors are constitutively expressed whereas the
majority is induced by interferon to elicit innate immunity.
In addition to a number of well-characterized interferon-
inducible antiviral factors such as RNaseL/OAS, ISG15,
Mx, PKR, and ADAR, tetherin (BST-2/CD317/HM1.24)
was recently discovered to block the release of enveloped
viruses from the cell surface, which is regarded as a novel
antiviral mechanism induced by interferon. Here, we briefly
review the history of tetherin discovery, discuss how
tetherin blocks virus production, and highlight the viral
countermeasures to evade tetherin restriction.
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Introduction
Interferon triggers innate immunity to protect cells from
viral infection. Production of interferon is initiated with
recognition of viral components, mainly viral nucleic acids,
by cellular pathogen recognition receptors that are located
on cellular membranes or within the cytosol (reviewed in
Kawai and Akira 2006; Douville and Hiscott 2010). For
example, membrane-associated Toll-like receptor 3 (TLR3)
recognizes double-stranded viral RNA, recruits TIR
domain-containing adaptor inducing IFN-β, and activates
the interferon regulatory factor 3 (IRF3) and nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB)
pathways to induce type I interferon production. TLR7 and
TLR9 are both located in endosomes. After recognizing
single-stranded viral RNA or double-stranded viral DNA,
they recruit myeloid differentiation primary response gene
88 and activate the IRF7 and NF-κB pathways. The
cytosolic retinoic-acid-inducible gene I and melanoma
differentiation-associated gene 5 recognize either double-
stranded viral RNA or 5′-triphospho viral RNA and activate
the MAVS (also known as IPS-1, VISA, and Cardif)
signaling transduction pathway, which leads to interferon
production.
Interferon binds to its receptor on the cell surface and
activates tyrosine kinase 2 and Janus kinase 1 that in turn
phosphorylates signal transducer and activator of transcrip-
tion 1 (STAT1) and STAT2. The phosphorylated STAT1/
STAT2 then translocates into the nucleus and forms the
interferon-stimulated gene factor 3 (ISGF3) complex
together with IRF9. The ISGF3 complex activates the
expression of a wide spectrum of genes, collectively named
interferon-stimulated genes (ISGs) that together establish an
antiviral state. Among hundreds of ISGs, those with well-
defined antiviral activities include RNaseL/OAS (2′,5′-
oligoadenylate synthetase), ISG15, myxovirus resistance
(Mx), protein kinase R (PKR), and adenosine deaminase,
RNA-specific (ADAR) that inhibit virus infection by
different mechanisms (reviewed in Sadler and Williams
2008). Upon binding to double-stranded RNA, OAS
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to and activate RNaseL. The activated RNaseL degrades
both cellular and viral RNA. ISG15 is conjugated to
cellular and viral proteins to modulate cellular response
and inhibit virus infection. This event is termed ISGylation
that is catalyzed sequentially by three enzymes called
ubiquitin E1 enzyme, E2-conjugating enzymes (such as
UBCH8), and E3 ligase enzymes (such as HERC5,
homologous to the E6-associated C terminus domain and
RCC1-like-domain-containing protein 5). Mx proteins are
dynamin-like large GTPases. They inhibit the infection of a
wide range of RNA and DNA viruses by binding to viral
nucleocapsids or other viral components and subsequently
trapping viral complexes as a result of Mx oligomerization.
PKR is a kinase that is dormant in its monomeric form.
Upon binding to viral double-stranded RNA, the kinase
activity is activated, which leads to phosphorylation and
dimerization of PKR. The activated PKR then phosphor-
ylates EIF2α and thus inhibits translation of cellular and
viral proteins. ADAR is an adenosine deaminase that binds
double-stranded RNA and converts adenosine to inosine. In
addition to these antiviral effectors, recent studies discov-
ered that an ISG named tetherin (also called BST-2/CD317/
HM1.24, bone marrow stromal cell antigen 2) inhibits viral
infection via a novel mechanism by blocking the release of
nascent enveloped viral particles from the cell surface.
Discovery of tetherin as an antiviral protein
BST-2 (or HM1.24) was first reported as a protein that
expresses at the surface of human plasma cell lines, bone
marrow stromal cell lines and B cells, and is thus
speculated to have a role in B-cell development (Goto et
al. 1994; Ishikawa et al. 1995). Its potential role as a
component of the host antiviral defense mechanism was
suggested by its being a target of the K5 protein (also
named MIR2) of Kaposi’s sarcoma-associated herpesvi-
rus (Bartee et al. 2006). The antiviral activity of BST-2
was subsequently demonstrated for its ability to inhibit the
release of HIV-1 that is deficient in Vpu and was therefore
given the name tetherin (Neil et al. 2008;V a nD a m m ee t
al. 2008).
In addition to structural and enzymatic proteins including
Gag, Pol, and Env, HIV-1 also encodes two regulatory
p r o t e i n sT a ta n dR e vt h a ta r ee s s e n t i a lf o rv i r a lg e n e
expression, as well as four accessory proteins named Vpr,
Vif, Vpu, and Nef that play important roles in HIV-1
pathogenesis (reviewed in Anderson and Hope 2004; Malim
and Emerman 2008). For example, Vif recognizes a cellular
cytidine deaminase named apolipoprotein B mRNA editing
enzyme, catalytic polypeptide 3 G (APOBEC3G), triggers
polyubiquitination of APOBEC3G through recruiting the
Cullin5-containing E3 ligase, and sends APOBEC3G to
proteasomes for degradation. In the absence of Vif,
APOBEC3G associates with HIV-1 RNP complex, gets
packaged into virus particles, and induces hypermutation of
viral cDNA by converting cytidines into uridines during
reverse transcription (reviewed in Henriet et al. 2009;
Niewiadomska and Yu 2009). It has been known for quite
a long time that Vpu is required for efficient HIV-1
production in certain cell lines such as HeLa and primary
T cells but not in cells such as HEK293 and COS-7 (Strebel
et al. 1989; Göttlinger et al. 1993). The Vpu-deficient HIV-
1 particles encounter a difficulty of leaving the surface of
Vpu-non-permissive cells such as HeLa. A dominant
cellular factor was speculated to underlie this restriction
activity because the restriction phenotype was recreated in
the HeLa/COS-7 heterokaryotic cells (Varthakavi et al.
2003). Subsequent studies revealed that this putative
restriction factor is interferon-inducible (Neil et al. 2007).
A long quest for this mysterious factor by several labs led
to the discovery of its identity as tetherin, named after its
function to tether nascent HIV-1 particles to the cell surface
(Neil et al. 2008; Van Damme et al. 2008). After this
finding, a variety of enveloped viruses were also shown to
be subject to the restriction of tetherin. These include HIV-2
(Le Tortorec and Neil 2009), simian immunodeficiency
virus (SIV) (Jouvenet et al. 2009), alpharetrovirus (Rous
sarcoma virus) (Jouvenet et al. 2009), betaretrovirus
(Mason-Pfizer monkey virus) (Jouvenet et al. 2009),
gammaretrovirus (human T-cell leukemia virus type 1
(HTLV-1)) (Jouvenet et al. 2009), filoviruses (Marburg
virus (Jouvenet et al. 2009; Sakuma et al. 2009) and Ebola
virus (Jouvenet et al. 2009;K a l e t s k ye ta l .2009)),
arenaviruses (Lassa virus (Sakuma et al. 2009)), and
herpesvirus (Kaposi’s sarcoma-associated herpesvirus
(KSHV) (Mansouri et al. 2009)). The two forthcoming
questions are how tetherin retains enveloped viral particles
to the cell surface and how viruses evade this restriction.
What is tetherin?
Human tetherin is encoded by a single copy of the bst-2
gene on chromosome 19p13.2 that is split into four exons
(Ishikawa et al. 1995). This gene is relatively non-
polymorphic with only one nonsynonymous single-
nucleotide polymorphism that is listed in the human
genome database and located in the coding region for the
ectodomain of tetherin. Tetherin orthologs are present in the
genomes of mammals but with significant sequence
divergence (McNatt et al. 2009).
Tetherin is constitutively expressed in mature B cells,
some cancer cell lines, bone marrow stromal cells,
monocyte-derived macrophages, and plasmacytoid dendrit-
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2005; Blasius et al. 2006; Mitchell et al. 2009; Miyagi et al.
2009). Interferon strongly stimulates tetherin expression
due to the presence of interferon response elements and a
binding site for STAT3 in the promoter region of bst-2 gene
(Blasius et al. 2006). However, the level of tetherin
expression as part of the interferon response appears to be
cell-type-dependent (Miyagi et al. 2009). Regarding cancer
T-cell lines, which are commonly used in laboratories to
study HIV infection, the basal expression levels of tetherin
vary but are all interferon-inducible (Neil et al. 2008;V a n
Damme et al. 2008; Rong et al. 2009).
When first described in B cells, tetherin was suggested to
be a marker for B-cell maturation (Ishikawa et al. 1995). Its
subsequent detection on multiple myeloma cells suggested
a tetherin-based therapeutic strategy to induce cell-mediated
cytotoxicity with tetherin antibody (Ozaki et al. 1997; Ono
et al. 1999). In an epithelial cell line, tetherin interacts and
modulates the subapical actin cytoskeleton, indirectly, via
RICH2, EBP50, and ezrin (Rollason et al. 2009). It remains
undetermined whether the cytoskeleton-modulating activity
is involved in tetherin’s function of restricting viral release.
Tetherin is also a ligand for immunoglobulin-like transcript
7 (ILT7) on pDCs (Cao et al. 2009). Since ILT7-mediated
signaling strongly inhibits production of interferon and
other cytokines in pDCs (Brown et al. 2004; Cao et al.
2006), tetherin may negatively regulate interferon and
cytokine production (Cao et al. 2009).
Tetherin localizes tothe plasma membrane, the trans-Golgi
network (TGN) and the early and recycling endosomes, and
cycles between these membrane compartments (Kupzig et al.
2003; Habermann et al. 2010). Endocytosis of tetherin from
the plasma membrane is clathrin-dependent and involves an
interaction of tetherin with the adaptor proteins AP-1 and
AP-2 (Rollason et al. 2007;M a s u y a m ae ta l .2009). In an
epithelial cell line, tetherin localizes to the apical membrane
following cellular polarization (Rollason et al. 2009). At the
cell surface, tetherin localizes to lipid rafts (Kupzig et al.
2003; Rollason et al. 2007, 2009; Goffinet et al. 2009).
Immunofluorescence microscopy reveals tetherin as punctual
clusters at the cell surface (Hinz et al. 2010). HIV-1 Gag
assembly and virus budding also occur at these membrane
microdomains (Waheed and Freed 2009). In addition, lipid
rafts are also involved in forming virological synapses and
promoting cell-to-cell transmission of viruses (Popik et al.
2002; Piguet and Sattentau 2004; Popik and Alce 2004;J o l l y
and Sattentau 2005).
How does tetherin block virus release?
Tetherin retains nascent viral particles at the cell surface by
linking them to the cellular membrane and to each other
(Fig. 1a). Electron microscopy shows accumulation of viral
particles at the surface of tetherin-expressing cells (Neil et
al. 2008; Perez-Caballero et al. 2009; Fitzpatrick et al.
2010). Tetherin is colocalized with viral Gag at the cell
surface (Neil et al. 2008; Van Damme et al. 2008; Perez-
Caballero et al. 2009) and is detected in the membrane of
viruses that are released from the cell surface either
spontaneously (Fitzpatrick et al. 2010; Habermann et al.
2010) or by shearing force (such as vortexing) (Miyagi et
al. 2009). Results of immunoelectron microscopy further
revealed that tetherin is located between the tethered viral
particles and between the tethered virus particle and the
plasma membrane, which indicates a direct role of tetherin
in blocking virus release. This conclusion is further
supported by two lines of evidence. First, human tetherin,
when expressed in non-human cells, can restrict release of
budding virions (Sato et al. 2009). Second and more
importantly, the antiviral function of tetherin is, to a certain
degree, independent of its sequence. An antiviral competent
artificial tetherin has been reported, which has its trans-
membrane domain derived from transferrin receptor, coiled-
coil domain from dystrophia myotonica protein kinase, and
glycophosphoinisitol (GPI) anchor from urokinase plasmin-
ogen activator receptor (Perez-Caballero et al. 2009). These
results suggest that the antiviral activity of tetherin unlikely
requires a co-factor.
Structural determinants of tetherin’s antiviral function Te-
therin is a type II transmembrane protein (Ishikawa et al.
1995; Kupzig et al. 2003). It bears a short cytoplasmic N-
terminal region, a transmembrane region, an ectodomain,
and a C-terminal GPI anchor (Kupzig et al. 2003). This
topology is rare and only shared with an isoform of the
prion protein (Hegde et al. 1998; Stewart et al. 2001).
Tetherin forms disulfide-linked dimers. It is heterogeneous-
ly glycosylated and thus migrates as 30–36-kDa proteins on
a sodium dodecyl sulfate–polyacrylamide gel. These struc-
tural features together determine tetherin’s antiviral function
and also regulate its sensitivity to different viral antagonists.
The short cytoplasmic domain (at amino acid positions 1
to 21) contains a conserved dual tyrosine motif (YXY6–8)
that is crucial for clathrin-mediated endocytosis through
recruiting AP-1 and AP-2 adaptor proteins (Rollason et al.
2007). The two lysine residues (at positions 18 and 21) are
ubiquitinized by the RING-CH K5 ligase of KSHV, which
leads to tetherin degradation (Mansouri et al. 2009; Pardieu
et al. 2010). Human tetherin lacks the 14-D/GDIWK-18
motif that constitutes the interaction site of Nef and is thus
resistant to Nef-mediated antagonism (Jia et al. 2009;
Zhang et al. 2009). Additionally, the cytoplasmic domain
of tetherin has been described to indirectly modulate
subapical actin cytoskeleton in polarized endothelial cells
via RICH2, EBP50, and ezrin (Rollason et al. 2009).
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43) consists of a single membrane-spanning helix. In the
case of HIV-1, the transmembrane region renders human
tetherin sensitive to Vpu-mediated downmodulation from
the cell surface and subsequent degradation (Gupta et al.
2009a; McNatt et al. 2009; Rong et al. 2009). Several
amino acid residues across the transmembrane domain of
tetherin have been reported to regulate the sensitivity to
Vpu and tetherin/Vpu interaction; these include L22, L23,
G25, I26, V30, I33, I36, and T45 (Fig. 2) (Gupta et al.
2009a; McNatt et al. 2009; Rong et al. 2009). Interestingly,
results of computer modeling of the structure of tetherin
transmembrane domain show that these amino acid residues
are positioned at one side of the helix, suggesting that they
may together form the contact site with Vpu (Fig. 2).
The ectodomain (amino acids 44 to 160) assumes a long
single α-helix as shown by the results of X-ray crystallog-
raphy (Fig. 3) (Hinz et al. 2010; Schubert et al. 2010; Yang
et al. 2010a). The complete ectodomain extends to a length
of 150 to 170Å which includes the 90-Å C-terminal coiled-
coil domain (Hinz et al. 2010). Two tetherin molecules
dimerize via this parallel disulfide-linked coiled-coil struc-
ture that is mainly stabilized by interactions throughout the
two-third C-terminal portion of the ectodomain (Fig. 3).
The N-terminal portion of ectodomain appears to be
relatively flexible at two hinges (positions A88 and G109)
and mediates the tetramerization of two tetherin dimers by
forming an antiparallel four-helix bundle (Fig. 3) (Hinz et
al. 2010; Schubert et al. 2010). Although two tetherin
dimers form a tetramer in crystals, mutants that are
deficient in tetramerization retain most of the antiviral
activity (Schubert et al. 2010;Y a n ge ta l .2010a). The
length of ectodomain is crucial for tetherin to block virus
release, which suggests a molecular ruler function to keep
the two membrane-spanning termini at a distance that is
required for maximal antiviral activity (Hinz et al. 2010;
Yang et al. 2010a).
The ectodomain of tetherin also contains three cysteines
(C53C63C91) that form disulfide bonds and therefore
stabilize tetherin homodimers. In addition, there exist two
sites for post-translational N-linked glycosylation (N65N92)
(Ohtomo et al. 1999;A n d r e we ta l .2009). While
glycosylation was shown to be dispensable for the antiviral
function, formation of at least one disulfide bond is crucial
for tetherin to block virus release (Andrew et al. 2009;
Perez-Caballero et al. 2009; Hinz et al. 2010).
The C-terminal region of tetherin contains a signal for
the addition of a GPI anchor. The nascent protein is
predictably cleaved at a serine residue (position 160) in
the endoplasmic reticulum (ER) followed by the attachment
Fig. 1 Antiviral mechanism of
tetherin. a Tetherin localizes to
the virus budding site and
incorporates into the viral
membrane. Tetherin exerts its
antiviral action by tethering viral
particles to the cell and to each
other. Further, tetherin inhibits
protease-mediated viral
maturation of released viral
particles. b, c Models of
molecular tethering mechanism.
Tetherin homodimers are likely
oriented in parallel. Tetherin
links viral particles to cells by
insertion of one terminus into
the virion membrane, while the
other is located in the cellular
membrane (b), or tetherin may
link viral particles and cells via
dimerization of the ectodomains
of monomers with both termini
inserted in either the virion
membrane or the cellular
membrane
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Therefore, the mature tetherin is a heterogeneously glycosy-
lated 160-amino-acid single pass transmembrane protein with
a C-terminal GPI anchor incorporated into lipid rafts. The GPI
anchor-mediated localization to lipid rafts promotes the
clathrin-mediatedendocytosis(Rollasonetal.2007). Removal
of GPI anchor abolishes the antiviral activity of tetherin (Neil
et al. 2008; Perez-Caballero et al. 2009).
Models of “tethering” Several models have been proposed
to illustrate how tetherin retains viral particles on the cell
surface. These models are conceived on the basis of two
key features of tetherin, dimerization across the ectodomain
and insertion of the two termini into either the cellular
plasma membrane or the membrane of viral particle. Since
not only does tetherin act as a link to retain a virus particle
to the cell surface but also tethers the viral particles to each
other, it is believed that the N and the C termini of tetherin
do not distinguish between the cellular and the viral
membranes for insertion, which is not surprising given that
viral membrane is derived from the cellular plasma
membrane (Fig. 1b, c) (Neil et al. 2008; Perez-Caballero
et al. 2009). Theoretically, a tetherin dimer may consist of
two monomers that are positioned either in a parallel or in
an antiparallel orientation. These two possibilities are now
resolved by the crystal structures of tetherin ectodomains
that are shown to form parallel dimers. Tetherin may thus
function as a parallel homodimer to bridge cellular and viral
membrane directly by insertion of one terminus into the
cellular membrane and the other into the viral membrane
(Fig. 1b). However, there is no conclusive evidence to rule
out the possibility that tetherin dimers work by inserting the
two termini of the same tetherin molecule into the same
membrane (Fig. 1c).
Fate of tethered viral particles T h et e t h e r e dv i r i o n sm a yb e
internalized and sent to late endosomes and lysosomes for
degradation(Neiletal.2007; Van Damme et al. 2008;S a t oe t
al. 2009). It was recently shown that internalization and
lysosomal degradation are promoted by the interaction of the
cytosolic domain of tetherin with breast cancer associated
gene 2 (Rabring7, ZNF364, RNF115) (Miyakawa et al.
2009). However, the molecular mechanisms behind this
remain unknown. Furthermore, it is unclear whether inter-
nalized virions can cycle back to the cell surface if not
degraded.
C
C
N
N
T45
L22
L23
V30
G25
I26
I33
I36 A14
A18
W22
Tetherin HIV-1 Vpu
Fig. 2 Models of tetherin and Vpu transmembrane domains. The
transmembrane domains of human tetherin (left) and HIV-1 Vpu
(right) are illustrated in regard to their orientation in the membrane.
Amino acids of the tetherin transmembrane known to impact on the
interaction without abruption of tetherin function are highlighted in
blue and indicated left to the model; amino acids are selected
according to Gupta et al. (2009a), McNatt et al. (2009), and Rong et
al. (2009). Amino acids that are involved in tetherin downmodulation
from the cell surface are highlighted in yellow on the Vpu
transmembrane model (Vigan and Neil 2010). Models were created
with PyMol software on the basis of the sequences of human tetherin
(GenBank ID NP_004326.1) and HIV-1 Vpu from viral clone pNL_4-3
(GenBank ID AAK08488.1)
Fig. 3 Crystal structure of tetherin ectodomain. Shown are the crystal
structures of a tetherin dimer (top) and tetramer (bottom). The
disulfide bond building cysteine residues C53C63C91 are highlighted
in blue (top and bottom); N-glycosylation sites N65N92 are presented
in purple (top). Structures are based on the X-ray crystallography data
from Schubert et al. (2010) (PDB ID: 3NWH) and were created using
PyMol software. Structures of the ectodomains were created using
PyMol software
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may affect cell-to-cell virus transmission. Cell-to-cell
transmission takes place through the intercellular contact
zones, termed virological synapses that temporarily connect
the infected cell to the uninfected one (reviewed in Piguet
and Sattentau 2004; Sattentau 2008; Martin and Sattentau
2009). Studies have been performed to assess the effect of
tetherin on cell-to-cell transmission of HTLV-1 and HIV-1.
Results showed that the tethered HTLV-1 particles on the
cell surface promote direct cell-to-cell spreading of HTLV-1
(Pais-Correia et al. 2009). In the case of HIV-1, two studies
reported a decreased cell-to-cell transmission as a result of
the presence of tetherin at virological synapse (Casartelli et
al. 2010; Kuhl et al. 2010b), whereas a third study observed
the opposite effect (Jolly et al. 2010). Furthermore, differ-
ences were reported regarding the impact of tetherin on the
infectivity of the transferred HIV-1 particles (Casartelli et
al. 2010; Jolly et al. 2010; Kuhl et al. 2010b). Since cell-to-
cell transmission is the predominant mode of HIV-1
spreading in cell culture and in secondary lymphoid tissues,
clarification of the role of tetherin in cell-to-cell dissemi-
nation of HIV-1 will be of great importance.
In addition to holding viral particles to the cell surface,
tetherin impairs the infectivity of Vpu-deficient HIV-1
particles that are released into the culture supernatant.
Several groups have observed that tetherin reduces the
levels of infectious Vpu-deficient HIV-1 particles to a more
severe degree rather than decreasing the total amounts of
virus particles as measured by viral CA(p24) or viral
reverse transcriptase activity, which implicates an adverse
effect of tetherin on the infectivity of progeny virions (Neil
et al. 2008; Van Damme et al. 2008; Perez-Caballero et al.
2009; Sauter et al. 2009). Further studies revealed a defect
in the morphology of cell-free HIV-1 particles that may
result from incomplete processing of viral Gag proteins
(Zhang and Liang 2010). The mechanism of this interfer-
ence, however, is not yet clear.
How do viruses evade tetherin restriction?
Viruses have evolved different strategies to evade
tetherin restriction. One common strategy that some
viruses share is to shut down the interferon pathway
such that tetherin is not induced for expression upon
viral infection (reviewed in Versteeg and García-Sastre
2010). With this mechanism, not only tetherin but also
other interferon-stimulated antiviral factors are not
expressed in virus-infected cells. On the other hand, some
viruses encode proteins that act as antagonists to counter-
act tetherin. The known tetherin antagonists include Vpu
of HIV-1, envelope protein of HIV-2, SIVtan and Ebola
virus, Nef of SIV, and K5 of KSHV. These viral proteins
overcome tetherin restriction by different mechanisms
(summarized in Fig. 4 and Table 1).
HIV-1 Vpu HIV-1 Vpu is the most extensively studied
tetherin antagonist among the others. Vpu is expressed
from the vpu–env bi-cistronic viral RNA as a 16-kDa
protein (reviewed in Bour and Strebel 2003; Malim and
Emerman 2008). Although it is translated at the late stage
of HIV-1 infection, Vpu is not found in virions. There
exists a 27-amino-acid transmembrane domain at the N
terminus of Vpu, followed by a 54-amino-acid cytoplasmic
domain that consists of two α-helices (the number of amino
acids refers to Vpu of the NL4-3 strain). It is worth noting
that there are two serine residues at positions 52 and 56 that
are located in the linker region of these two helices and are
subject to phosphorylation. It is well documented that Vpu
downregulates CD4 at the ER and thus prevents premature
binding of viral gp160 with CD4. This function of Vpu
initiates with recognition of the cytoplasmic tail of CD4 and
recruitment of β-TrCP (a human beta transducin repeat
containing protein) that is a key component of the E3
ubiquitin ligase complex (Skp1, Cullin1, and β-TrCP). The
phosphorylated S52 and S56 residues of Vpu constitute the
binding site for β-TrCP that subsequently causes poly-
ubiquitination and proteasomal degradation of CD4.
The second prominent function of Vpu is to promote
HIV-1 release by counteracting tetherin (Neil et al. 2008;
Van Damme et al. 2008). One mechanism underlying this
function of Vpu is to downregulate cell surface expression
of tetherin and therefore removes tetherin from HIV-1
assembly and budding site on the plasma membrane (Van
Damme et al. 2008; Perez-Caballero et al. 2009). The
existence of additional mechanisms is also suggested by the
observation of a significant level of tetherin incorporation
into wild-type HIV-1 particles (Habermann et al. 2010).
More importantly, Vpu enhances virus production in T-cell
lines such as CEMx174 and H9 cells without reducing cell
surface expression of tetherin (Miyagi et al. 2009).
Vpu may achieve tetherin downregulation from the cell
surface by two mechanisms, depletion of the intracellular
tetherin pool and sequestration of tetherin at the TGN. Vpu
that is either produced from an expression vector or from
HIV-1 proviral DNA is capable of diminishing the total
amounts of tetherin in cells. This activity of Vpu relies on
the recruitment of β-TrCP (Douglas et al. 2009; Mangeat et
al. 2009; Mitchell et al. 2009). Mutating the S52/S56
residues of Vpu or depleting β-TrCP with small interfering
RNA oligos significantly attenuates Vpu’s antitetherin
activity. In addition, expression of a dominant negative
mutant of β-TrCP such as β-TrCP-ΔF also cripples the
ability of Vpu to counteract tetherin. However, mutation of
the only two lysine residues, the most common ubiquitin
receptor, within the cytoplasmic tail of tetherin fails to
J Neuroimmune Pharmacol (2011) 6:188–201 193render the mutated tetherin resistant to Vpu-mediated
degradation. The major Vpu-responsive site has now been
mapped to the STS motif (positions 3 to 5) that undergoes
Vpu/β-TrCP-dependent ubiquitination (Tokarev et al.
2010).
Vpu-mediated tetherin degradation may require either
the proteasomal or the endosomal/lysosomal pathway.
Interestingly, blocking either of these two degradation
pathways by specific inhibitors in different cell lines
rescues Vpu-mediated tetherin degradation, albeit the extent
of rescue varies due to specific experimental settings.
Concanamycin A (ConA) is an inhibitor of the endo-
somal/lysosomal pathway and was observed to stabilize
tetherin in the presence of Vpu (Douglas et al. 2009).
Bafilomycin A1 (BafA1) reverses the cell surface and
intracellular downregulation of tetherin by Vpu (Mitchell et
al. 2009). Both BafA1 and ConA inhibit the endosomal
vacuolar ATPase and prevent acidification of endosome and
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Fig. 4 Illustration of viral counter measures against tetherin. The
normal cellular trafficking of tetherin is depicted from the endoplas-
mic reticulum (ER) to the Golgi apparatus, to the plasma membrane,
and then through recycling endosomes. This trafficking is interrupted
by several viral proteins that have been identified to antagonize
tetherin. Vpu may sequester tetherin at the TGN or recruit β-TrCP to
ubiquitinate tetherin and target it for degradation via the lysosomal or
proteasomal pathway. Nef interacts with the cytoplasmic tail of
tetherin and triggers tetherin downregulation from the cell surface.
SIV/HIV-2/Ebola envelope proteins may sequester tetherin at the
TGN/perinuclear regions. K5 ubiquitinates tetherin and causes tetherin
degradation in lysosomes
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protease inhibitor cocktail of leupeptin, pepstatin A, and
E64d also supports the role of endosomal/lysosomal
pathway in Vpu-mediated degradation of tetherin (Iwabu
et al. 2009). Finally, knockdown of the μ2 subunit of the
AP-2 adaptor complex partially prevents the Vpu-induced
tetherin downregulation (Mitchell et al. 2009).
MG-132 has been used in several studies as a protea-
some inhibitor to prevent tetherin degradation by Vpu, but
the results showed varying degrees of efficacy (Van
Damme et al. 2008; Goffinet et al. 2009; Mangeat et al.
2009; Mitchell et al. 2009). It is noted that long-term
treatment with MG-132 may deplete the intracellular pool
of free ubiquitin and thus affect the ubiquitin-dependent
degradation by either the proteasomes or the lysosomes
(Van Damme et al. 2008; Douglas et al. 2009; Mitchell et
al. 2009). Given the important role of β-TrCP and
ubiquitination in the degradation of tetherin by Vpu, results
obtained with MG-132 treatment alone may not be
sufficient to distinguish between the roles of proteasomal
or endolysosomal pathway in tetherin degradation. The use
of the other proteasome inhibitors ALLN and clasto-
lactacystin β-lactone (inhibitor of the 20S proteasome)
increases the level of intracellular tetherin in the presence or
the absence of Vpu (Goffinet et al. 2009). Notably, both
proteasome inhibitors abolish the ability of Vpu to rescue
viral release in the presence of tetherin (Goffinet et al.
2009). It is possible that both the proteasomal and the
endolysosomal pathways are involved in Vpu-mediated
degradation of tetherin, albeit likely to varying degrees in
different cell lines.
In addition to degradation, Vpu may disturb tetherin
trafficking in cells and sequester tetherin away from the
plasma membrane. Tetherin is normally localized to the
plasma membrane and to, a less degree, in the perinuclear
regions. Vpu causes a relocalization of tetherin from the
plasma membrane to the TGN where tetherin is sequestered
(Dubé et al. 2010). Results of immunoelectron microscopy
showed an increased presence of tetherin at the early/
recycling endosomes when Vpu is expressed (Habermann
et al. 2010). It is conceivable that Vpu interacts with
tetherin and diverts the trafficking of tetherin toward
specific intracellular membrane compartments for seques-
tration or degradation.
Vpu likely recognizes tetherin through an interaction
between the transmembrane domains of these two proteins.
This scenario was first suggested by the finding that HIV-1
Vpu is unable to counteract tetherin from monkeys such as
Table 1 Summary of viral tetherin antagonists
Tetherin
antagonists
Tetherin
surface
downregulation
Tetherin
intracellular
depletion
Target domain
in tetherin
Intracellular
relocalization
of tetherin
Species
specificity
References
HIV-1 Vpu Yes Yes TM domain TGN Yes Neil et al. (2008), Van
Damme et al. (2008),
Mitchell et al. (2009),
Goffinet et al. (2009),
Douglas et al. (2009),
Mangeat et al. (2009),
Iwabu et al. (2009),
Dubé et al. (2010)
SIVcpz/gor Vpu ? ? ? ? Yes Sauter et al. (2009),
Yang et al. (2010b)
SIVgsn/mus/mon Nef ? ? Cytoplasmic tail
(G/DDIWK)
? Yes Sauter et al. (2009),
Yang et al. (2010b)
SIVmac/smm Nef Yes ? Cytoplasmic tail
(GDDIWK)
? Yes Jia et al. (2009),
Zhang et al. (2009)
SIVagmSab/Tan Nef ? ? Cytoplasmic tail
(DDICK)
? Yes Zhang et al. (2009)
HIV-2 Env Yes No Ectodomain TGN No Le Tortorec and Neil (2009),
Jia et al. (2009),
Hauser et al. (2010),
Abada et al. (2005)
Ebola GP No No ? ? No Kaletsky et al. (2009),
Lopez et al. (2010)
SIVtan Env Yes No Ectodomain Perinuclear region No Gupta et al. (2009b)
KSHV K5 Yes Yes Cytoplasmic tail(K18) Late endosomes Yes Mansouri et al. (2009),
Pardieu et al. (2010)
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2009a;M c N a t te ta l .2009;R o n ge ta l .2009). This
resistance phenotype of monkey tetherin to HIV-1 Vpu
was subsequently mapped to a few amino acid residues in
the transmembrane domain of tetherin, which are divergent
from their counterparts in the human tetherin transmem-
brane domain (Gupta et al. 2009a; Jia et al. 2009; McNatt et
al. 2009; Zhang et al. 2009). A detailed mutagenesis
analysis of the Vpu transmembrane domain also identified
several residues that determine Vpu’s tetherin antagonism
activity (Vigan and Neil 2010). The Vpu mutants A14L,
W22A, A14L/W22A, and, to a minor extent, A18L lost
their ability to counteract tetherin (Vigan and Neil 2010).
Further experiments showed that these Vpu mutants were
crippled in downregulating tetherin from cell surface and
were impaired in binding to tetherin. It is worth noting that
the W22A mutant is also defective in downregulating CD4
from cell surface (Vigan and Neil 2010). In solid-state
NMR structures of Vpu transmembrane multimers, A14,
A18, and W22 line up on the outside-facing side of the
helices (Park et al. 2003; Vigan and Neil 2010). These
amino acid residues are likely involved in forming the
interaction interface between the Vpu and the tetherin
transmembrane helices (Fig. 2). In support of their
importance in Vpu function, A18 and W22 are highly
conserved in HIV-1 isolates that have retained the ability to
antagonize tetherin. A detailed understanding of Vpu/
tetherin interaction across their transmembrane domains
requires further characterization of the involved amino acid
residues in the tetherin transmembrane domain and struc-
tural determination of the Vpu/tetherin transmembrane
domain complex. It also remains to be determined when
and where Vpu initiates interaction with tetherin and how
the Vpu/tetherin complex is retained at TGN and early/
recycling endosomes.
SIV Nef SIV strains with the exception of SIVcpz, SIVgor,
SIVgsn, SIVmus, and SIVmon do not contain a Vpu gene
(Gao et al. 1999; Courgnaud et al. 2002, 2003). Vpu of
SIVgsn/mus/mon antagonizes tetherin whereas SIVcpz/gor Vpu
does not overcome tetherin (Sauter et al. 2009). Therefore,
SIV should have an alternative strategy to counteract
tetherin. Indeed, Nef proteins from SIV strains including
SIVmac,S I V smm, SIVblu, and SIVagm are able to overcome
restriction by their respective species tetherin but are unable
to overcome human tetherin (Jia et al. 2009; Zhang et al.
2009). Interestingly, Nef proteins from HIV-2 and HIV-1
are also able to counteract Old World monkey tetherins
(Rhesus macaque and Sooty mangabey) but are less
efficient than SIV Nef (Jia et al. 2009). The sensitivity
determinant in simian tetherin to SIV Nef has been mapped
to a five-amino-acid region (14-G/DDIWK-18) in the
cytoplasmic domain, which is, however, absent in human
tetherin (Jia et al. 2009; Zhang et al. 2009). This is in
contrast to the role of transmembrane domain of human
tetherin in determining its sensitivity to HIV-1 Vpu (Jia et
al. 2009; McNatt et al. 2009). Mutating the myristoylation
site and cholesterol recognition motif in Nef impairs its
tetherin antagonism activity (Jia et al. 2009; Zhang et al.
2009). Additionally, mutations that abrogate CD4 and
CD28 downregulation activity of SIVmac239 Nef also
diminish the antagonism of Rhesus tetherin, whereas MHC-
I downregulation is not associated with tetherin-
antagonizing function (Jia et al. 2009; Zhang et al. 2009).
It is believed that SIV Nef protein counteracts simian
tetherin by recognizing the “G/DDIWK” motif and down-
regulating tetherin from the cell surface.
Envelope proteins of HIV-2, SIV, and Ebola virus The
envelope glycoproteins (GP) of several viruses have been
implicated in tetherin antagonism. A common feature
among these tetherin antagonists is that they all seem to
target the tetherin ectodomain and cause the relocalization
of tetherin from the plasma membrane to the perinuclear
region, a strategy that is similar to what Vpu employs to
antagonize human tetherin.
HIV-2 Env Unlike HIV-1, HIV-2 does not encode a vpu
gene. Instead, HIV-2 Env fulfills Vpu function to promote
virus release (Bour et al. 1996, 2003; Bour and Strebel 1996,
2003). Further studies demonstrate that HIV-2RodA/Rod10
Env accomplishes this function also by counteracting
tetherin (Le Tortorec and Neil 2009;H a u s e re ta l .2010).
Yet this activity of HIV-2 envelope protein seems to be cell-
type dependent, since the endogenous tetherin in HeLa cells
but not the ectopically expressed tetherin in 293Tcells is
counteracted by HIV-2 Env. It is noted that HIV-1 Env and
SIVmac Env do not exhibit antitetherin activity (Le Tortorec
and Neil 2009). The endocytic motif GYxxθ within the
cytoplasmic tail as well as the extracellular motifs deter-
mines the antagonism activity of HIV-2 Env toward human
tetherin (Le Tortorec and Neil 2009). In HIV-2Rod10 Env, a
mutation in the membrane-proximal motif Y707 is sufficient
to abrogate its antitetherin activity (Hauser et al. 2010). A
point mutation A100D in the ectodomain of human tetherin
is sufficient to render tetherin resistant to HIV-2 Env;
however, both Ebola GP and HIV-1 Vpu were able to
antagonize this mutant (Lopez et al. 2010). Tetherin was
additionally shown to co-immunoprecipitate with HIV-2 Env
likely through interaction between their extracellular
domains, and tetherin was consequently downregulated from
the cell surface (Le Tortorec and Neil 2009). HIV-2 Env
does not cause intracellular depletion of tetherin but does
lead to sequestration of tetherin at the TGN (Le Tortorec
and Neil 2009). Additionally, Env from another isolate,
HIV-2ROD14, is unable to enhance viral release in cells
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2005;B a r t e ee ta l .2006; Jia et al. 2009). This defect seems
to result from a point mutation at position 598 of HIV-2Rod14
Env (Abada et al. 2005;B a r t e ee ta l .2006).
SIV Env The envelope glycoprotein from SIVtan (Tantalus
monkeys) antagonizes tetherin from human and different
monkey species including Tantalus, Rhesus, and Sooty
mangabey (Gupta et al. 2009b). SIVtan Env appears to
employ a similar antagonizing mechanism by downregulat-
ing the cell surface tetherin, but it does not cause depletion
of intracellular tetherin. However, studies do show that
SIVtan Env causes relocation of human tetherin from the
plasma membrane to the perinuclear region in 293T cells. A
point mutation of the ectodomain of human tetherin
(A100D) confers resistance to SIVtan Env, suggesting the
ectodomain as a possible target of SIVtan Env (Gupta et al.
2009b). Whether other SIV strains also employ Env to
counteract tetherin is currently unknown. At least, deletion
of env in SIVmac or SIVagm does not increase virus
sensitivity to tetherin (Jia et al. 2009; Zhang et al. 2009;
Lim et al. 2010). It seems that SIV uses Nef protein more
widely than Env protein to counteract tetherin.
Ebola GP Tetherin restricts the release of Ebola virus-like
particles, and this restriction is overcome by Ebola GP
(Kaletsky et al. 2009). It is striking that Ebola GP is able to
circumvent tetherin from different species including human
and murine as well as a series of functional tetherin
derivatives including the active artificial tetherin (Lopez et
al. 2010). A mutant GP that is retained at the ER by an ER
retention signal is unable to overcome tetherin restriction,
suggesting that correct localization of GP is necessary for
its antagonism activity. GP antagonism of tetherin does not
seem to affect intracellular levels of tetherin (Kaletsky et al.
2009; Lopez et al. 2010), nor does it require cell surface
tetherin downregulation (Lopez et al. 2010). Overall, Ebola
GP appears to overcome a broad spectrum of tetherin via a
mechanism that is distinct from that shared by the Env of
HIV-2 and SIVtan.
KSHV K5 KSHV expresses two RING-CH (MARCH) E3
ubiquitin ligases called K3/MIR1 and K5/MIR2. K5 has
long been known to downregulate a number of cell surface
proteins including MHC-I (Coscoy and Ganem 2000;
Ishido et al. 2000; Stevenson et al. 2000). In a proteomics
screening, tetherin was identified as a target of K5 down-
regulation from the cell surface (Bartee et al. 2006).
Subsequent to the discovery of tetherin as a viral restriction
factor, K5 was reported to overcome tetherin restriction and
restore viral release (Mansouri et al. 2009; Pardieu et al.
2010). K5 exerts its antagonism activity by downregulating
tetherin from the cell surface (Mansouri et al. 2009; Pardieu
et al. 2010). This activity of K5 requires its RING domain
that mediates the ubiquitination of the lysine residue at
position 18 within tetherin cytoplasmic tail (Pardieu et al.
2010). This ubiquitinated tetherin is then sorted into CD63-
positive late endosomal compartment for degradation
(Pardieu et al. 2010). A dominant negative form of VPS4
prevents cell surface depletion of tetherin by K5 (Pardieu et
al. 2010). Since this VPS4 mutant disrupts the multi-
vesicular body (MVB) pathway, the results suggest that K5
redirects tetherin from the cell surface through the MVB
pathway to late endosomes for degradation.
Tetherin is adapted to viral antagonists and shaped HIV
evolution
Tetherin and other host cell restriction factors have co-
evolved with viruses. The selective pressure from viruses
has lead to species specificity and diversity in restriction
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Fig. 5 Sequence alignment of primate tetherins. Aligned are tetherin
amino acid sequences of selected simians from the Old World monkey
lineage (SMN Sooty mangabey; AGM African green monkey; MAC
Rhesus macaque) and hominid lineage (CPZ chimpanzee; gorilla;
human). Highlighted are the domains that determine sensitivity to Nef
(yellow), the cysteines that are involved in tetherin dimerization via
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disulfide bonds (blue), and the GPI anchor attachment site (green).
Alignment was created using ClustalX software; sequence files are
derived from GenBank: SMN, ADI58600.1; AGM, ADI58599.1;
MAC, ADI58602.1; CPZ, ADI58593.1; Gorilla, ADI58594.1;
Human, NP_004326.1factors with common ancestors; a sequence alignment of
primate tetherins is shown in Fig. 5. Tetherin has also
evolved under positive selection by viral antagonists
(McNatt et al. 2009; Sauter et al. 2009; Lim et al. 2010).
Evolutionary analysis revealed a positive selection at amino
acid position 9 in the cytosolic domain of New World
monkey tetherin; this was not seen with tetherins of Old
World monkeys and hominids (Lim et al. 2010). Instead,
tetherin amino acid position 17 has undergone positive
selection in Old World monkeys and hominids, in addition
to a deletion of five amino acids surrounding this position
(14-DDIWK-18) in human tetherin (Lim et al. 2010). It is
believed that the positive selection has been driven by an
ancient Nef-like antagonist of tetherin (Lim et al. 2010).
Interestingly, Vpu does not seem to have impacted on
tetherin evolution in Old World monkeys or hominids, but
this might be due to the short period of time since the gain-
of-function evolution in Vpu (Lim et al. 2010).
HIV-1 was originated by cross-species transmission of
SIV from chimpanzees to humans (Gao et al. 1999). SIVcpz
is considered to have evolved from a recombination of two
SIV strains, SIVgsn and SIVrcm. SIVgsn but not SIVrcm
encodes Vpu (Courgnaud et al. 2002, 2003; Dazza et al.
2005). SIVcpz obtained Vpu from SIVgsn and Nef from
SIVrcm. It is speculated that, in the original SIVcpz, Vpu and
Nef proteins had only little antitetherin capacity (Sauter et
al. 2009; Yang et al. 2010b). Over time, SIVcpz Nef evolved
to become the primary tetherin antagonist, while Vpu
maintained the capacity to downmodulate CD4 from the
cell surface (Sauter et al. 2009; Yang et al. 2010b). When
SIVcpz crossed the species barrier to infect humans, Nef
was unable to antagonize human tetherin due to the lack of
the Nef-sensitive 14DDIWK18 site. Vpu subsequently (re)
gained its tetherin-antagonizing function (Sauter et al.
2009; Zhang et al. 2009; Lim et al. 2010). However, only
the Vpu of pandemic HIV-1 group M efficiently antago-
nizes human tetherin whereas Vpu of group N and O is a
poor tetherin antagonist (Sauter et al. 2009). This suggests
that the extent of Vpu adaptation to antagonize human
tetherin influences the pathogenicity of HIV-1.
In contrast to SIVcpz, the SIVsmm strain that gave rise to
HIV-2 lacks vpu (Gao et al. 1992; Chen et al. 1997). HIV-2
overcame human tetherin restriction through evolving its
envelope protein into a tetherin antagonist (Le Tortorec and
Neil 2009). This adaptation, however, might involve a
fitness cost, which is reflected by the low infectivity of
HIV-2 when compared to HIV-1. Nonetheless, this flexi-
bility in viral strategy to antagonize tetherin reflects the
intense selective pressure exerted by tetherin during the
adaptation of the HIV-1 and HIV-2 precursor viruses to the
new host. Considering the high conservation of tetherin in
various species and its restrictive nature over a wide range
of enveloped viruses, the example of shaping HIV-1 and
HIV-2 evolution suggests a highly active role of tetherin-
mediated innate immunity against cross-species transmis-
sion of viruses beyond HIV (McNatt et al. 2009; Sauter et
al. 2009; Lim et al. 2010; Yang et al. 2010b).
Concluding remarks
Since the discovery of the potent antiviral activity of tetherin,
efforts are already underway to exploit Vpu/tetherin interac-
tion as a new target to develop novel anti-HIV-1 therapeutics
such as small compounds that block Vpu function and thus
expose HIV-1 to tetherin restriction. Similar approaches have
been proven successful in the development of small molecule
inhibitors of Vif/APOBEC3G interaction (Nathans et al.
2008; Cen et al. 2010). It has already been reported that a
Vpu-targeting drug BIT225 inhibited the release of HIV-1
from macrophages (Khoury et al. 2010). However, protease
inhibitors, which modulate transmembrane transporters and
thereby might also interfere with Vpu, proved not to impact
on tetherin cell surface expression or Vpu-mediated down-
modulation of tetherin (Kuhl et al. 2010a).
It is noted that the anti-HIV-1 activity of tetherin and the
Vpu antagonism have been investigated thus far mainly in
cultured cell lines including HeLa, 293T, COS-7, HT1080,
CEMx174, H9, and SupT1 cells. The results thus obtained
need to be verified by experiments in primary human
immune cells such as CD4+ T cells and macrophages
partially because some observations have been cell-type-
specific. For instance, although HIV-1 replication is Vpu-
responsive in CEMx174 and H9 cells, the cell surface level of
tetherin is not affected by Vpu expression as opposed to the
downregulation of cell surface tetherin by Vpu in HeLa and
293Tcells (Miyagi et al. 2009; Van Damme et al. 2008). The
physiological role of tetherin in the pathogenesis of HIV-1
and other enveloped viruses also remains to be determined in
animal models. Although tetherin potently blocks the release
of virus particles from cell surface and thus restricts
dissemination of free virus particles, further investigation is
needed to clarify its role in cell-to-cell virus transmission that
is much more efficient than transmission by free virus
particles.
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